| Autor: |
Silva VSE; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-900, Brazil., Abdallah EA; International Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil., Brito ABC; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-900, Brazil., Braun AC; International Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil., Tariki MS; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-900, Brazil., de Mello CAL; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-900, Brazil., Calsavara VF; International Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil., Riechelmann R; Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-900, Brazil., Chinen LTD; International Research Center, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil. |
| Abstrakt: |
The discovery of predictive biomarkers in metastatic colorectal cancer (mCRC) is essential to improve clinical outcomes. Recent data suggest a potential role of circulating tumor cells (CTCs) as prognostic indicators. We conducted a follow-on analysis from a prospective study of consecutive patients with mCRC. CTC analysis was conducted at two timepoints: baseline (CTC1; before starting chemotherapy), and two months after starting treatment (CTC2). CTC isolation/quantification were completed by ISET ® (Rarecells, France). CTC expressions of drug resistance-associated proteins were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Seventy-five patients were enrolled from May 2012 to May 2014. A CTC1 cut-off of >1.5 CTCs/mL was associated with an inferior median OS compared to lower values. A difference of CTC2-CTC1 > 5.5 CTCs/mL was associated with a reduced median PFS. By multivariate analysis, CTC1 > 1.5 CTCs/mL was an independent prognostic factor for worse OS. Multi-drug resistance protein-1 (MRP-1) expression was associated with poor median OS. CTC baseline counts, kinetics, and MRP-1 expression were predictive of clinical outcomes. Larger studies are warranted to explore the potential clinical benefit of treating mCRC patients with targeted therapeutic regimens guided by CTC findings. |
